Demonstrating its continued and sustained impact on the lives of people in low- and middle-income countries (LMICs) across the world, the Medicines Patent Pool (MPP) today publishes its 2025 annual report, From Innovation to Access.

MPP’s 2025 Annual Report

The report shows how, between 2023 and 2025 – the three years of its most recent strategic period -MPP through its partners has: 

  • Enabled the supply of nine new products to LMICs, surpassing its strategic target. 
  • Successfully concluded six new licence agreements. 
  • Enabled 13 LMIC manufacturers to receive mRNA technology transfer training, exceeding the strategic target of 10.  

In 2025 alone, MPP continued to deliver high-impact results across priority areas, reinforcing its role as a trusted partner in expanding equitable access to health technologies: 

  • An estimated 26 million people in 129 LMICs – an increase of three million people since 2024 – now have access to the MPP-enabled dolutegravir, the central building block of WHO-recommended treatment options.   
  • A new licence agreement was signed with ViiV Healthcare to allow generic manufacturers to develop, manufacture and supply long-acting injectable cabotegravir (CAB-LA) for HIV treatment in combination with long-acting injectable rilpivirine (RPV-LA) in LMICs.  
  • Newly updated WHO guidelines mean that TAF-ED and TAF-LD – two MPP-enabled products – are now on an equal footing with TLD as the preferred first-line HIV treatment option.  
  • The MPP-enabled pALD (paediatric ABC/3TC/DTG 60/30/5mg dispersible tablet) – the first complete dispersible paediatric fixed-dose combination HIV treatment – surpassed pDTG in the volume of orders to MPP’s generic manufacturers. PALD is now the most widely used paediatric HIV drug formulation in LMICs, and has already been supplied in 47 countries in just two years.  
  • Cancer patients in El Salvador, Indonesia and the Philippines gained access to quality-assured generic nilotinib, a treatment for chronic myeloid leukaemia (CML) made possible by MPP’s agreement with the originator company Novartis in 2022. By the end of the year, 1.2 million nilotinib capsules had been supplied in these three countries, equivalent to treating approximately 800 patients for a full year of CML therapy.  
  • Three of the 13 MPP Technology Transfer Programme Partners – Biovac, Sinergium and Bio-E – completed a successful mRNA technology transfer and have produced their first batches.  
  • The Medicines Patents and Licences (MedsPaL) database, the world’s leading tool on patent and licence information for LMICs, now covers over 32,000 patent applications for 208 health products across 203 patent jurisdictions. 
     

Commenting, MPP’s Executive Director, Charles Gore said: “Despite a complex global environment, MPP has continued to deliver strong results and expand access to essential health technologies. Our achievements in 2025 reflect the strength of our partnerships and our focus on impact. With our new Strategy 2026–2030, we are well positioned to build on this momentum and extend our reach even further.“ 

The report further shows that between its inception in 2010 and the end of 2025, MPP’s impact has seen:  

  • 62.14 billion doses of treatment supplied to 148 LMICs through MPP’s licensees.  
  • 44 products licensed through MPP’s agreements with 22 innovators.  
  • 6.7 million more patient-years treated than would have been the case in the absence of MPP’s licensing agreements. 
  • 1.4 million disability-adjusted life years (DALYs) averted.  
  • 540,000 HIV virological failures averted.  
  • US$ 2.6 billion saved by the global community.  
  • US$ 12 billion in theoretical expenditures avoided.